NCT06771141

Brief Summary

Brief Summary: Clinical Study The purpose of this clinical study is to evaluate whether the use of virtual reality (VR) before endoscopy reduces anxiety levels and positively impacts vital signs in children. This study aims to answer the following key questions: Does the VR application reduce pre-endoscopy anxiety in children? Does the VR application improve vital signs such as heart rate, blood pressure, and oxygen saturation in children? Researchers will compare the effects of the VR application with standard care to assess its effectiveness. Participants: The experimental group will undergo a 15-minute VR session before the endoscopy. The control group will receive standard care without VR. Anxiety levels and vital signs will be measured throughout the study. This study aims to explore whether VR technology can serve as an effective stress management tool during pediatric medical procedure

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 29, 2024

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 26, 2024

Completed
19 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 15, 2024

Completed
24 days until next milestone

First Submitted

Initial submission to the registry

January 8, 2025

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 13, 2025

Completed
Last Updated

January 14, 2025

Status Verified

July 1, 2024

Enrollment Period

4 months

First QC Date

January 8, 2025

Last Update Submit

January 10, 2025

Conditions

Keywords

Virtual Reality, Anxiety, Endoscopy, Pediatric, Vital Signs

Outcome Measures

Primary Outcomes (1)

  • Reduction in Anxiety Levels in Pediatric Patients

    The primary outcome measure is the change in anxiety levels among pediatric patients undergoing endoscopy. Anxiety levels will be assessed using the State-Trait Anxiety Inventory for Children (STAIC), a validated tool for measuring anxiety in children. Scores will be measured before and after the intervention to determine the effectiveness of the virtual reality (VR) application compared to the control group receiving standard care.

    Anxiety levels will be measured immediately before the intervention and immediately after the intervention on the same day as the endoscopy procedure.

Study Arms (2)

Virtual Reality Intervention Group

EXPERIMENTAL

This arm includes participants who will receive a 10-minute virtual reality (VR) session before their endoscopy procedure. The VR intervention aims to reduce anxiety and stabilize vital signs (e.g., systolic/diastolic blood pressure, heart rate, oxygen saturation) by providing an immersive and interactive experience designed to distract and relax the participants. Anxiety levels and vital signs will be measured pre- and post-intervention to evaluate its effectiveness.

Behavioral: Virtual Reality Video Session

Standard Care Control Group

NO INTERVENTION

Participants in this group will receive standard care prior to the endoscopy procedure, without the VR intervention. Anxiety levels and vital signs will be measured at similar intervals to compare with the experimental group.

Interventions

This intervention involves a 10-minute virtual reality (VR) video session designed to reduce pre-procedural anxiety and promote relaxation in pediatric patients. The video immerses participants in a calming virtual environment with interactive and visually engaging content tailored for children. It is administered prior to the endoscopy procedure to help manage anxiety and stabilize vital signs, such as blood pressure, heart rate, and oxygen saturation. The VR session serves as a non-pharmacological approach to anxiety management during medical procedures.

Virtual Reality Intervention Group

Eligibility Criteria

Age8 Years - 17 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Children aged 8 to 17 years.
  • Scheduled to undergo an endoscopy procedure.
  • Able to provide assent, and their parents or legal guardians provide written informed consent.
  • No prior exposure to virtual reality applications.
  • Willing to participate in the study.

You may not qualify if:

  • Presence of a chronic medical condition affecting cardiovascular or respiratory systems.
  • Diagnosed with a severe psychiatric disorder.
  • Known visual or auditory impairments that could prevent participation in a virtual reality session.
  • History of seizures or epilepsy.
  • Unwillingness to participate or inability to comply with study procedures.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Van Yüzüncü Yıl Üniversity

Van, Van, 65000, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Anxiety Disorders

Condition Hierarchy (Ancestors)

Mental Disorders

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: his study uses a randomized controlled trial (RCT) design with a parallel assignment model. Participants are divided into two groups: the intervention group, which receives a virtual reality (VR) application before undergoing endoscopy, and the control group, which receives standard care. The study is open-label, meaning both participants and researchers are aware of the group assignments. This design allows for a direct comparison of the effects of the VR application on anxiety levels and vital signs in pediatric patients.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD

Study Record Dates

First Submitted

January 8, 2025

First Posted

January 13, 2025

Study Start

July 29, 2024

Primary Completion

November 26, 2024

Study Completion

December 15, 2024

Last Updated

January 14, 2025

Record last verified: 2024-07

Data Sharing

IPD Sharing
Will not share

Individual Participant Data (IPD) will not be shared to prioritize the privacy and confidentiality of participants. Additionally, it has been specified in the ethical approval that the data will only be used for the purposes of this study and will not be shared with third parties.

Locations